Brad Howell’s Post

View profile for Brad Howell, graphic

Building World-Class Data Science Teams in Biotech

IPO fever seems to be setting in already! Last year only 22 drugmakers priced new offerings which was the lowest total in 6 years. Already in 2024, 5 companies have jumped into the mix meaning a much more promising start and giving an optimistic outlook for 2024 (hopefully!). ◼ Alto Neuroscience – 2 months after closing a $45 million Series C, they’re preparing an IPO to push precision psychiatry therapies through the clinic ◼ ArriVent Biopharma – hoping to net over $156 million to support the development of their drug for NSCLC patients ◼ CG Oncology – aiming for a $1 billion valuation to continue their work developing a therapy for patients with bladder cancer ◼ Kyverna Therapeutics – looking to fund their cell therapy work led by their experimental lupus treatment ◼ Metagenomi – last year they raised $275 million in their Series B and they have now filed to bring their work on identifying new CRISPR enzymes for gene editing, public I think this sets up 2024 to be a much better year than the last! Any thoughts? Let me know in the comments. #ipo #biotech #funding

2024 Brings Surprising Early Surge of Biotech IPOs | BioSpace

2024 Brings Surprising Early Surge of Biotech IPOs | BioSpace

biospace.com

To view or add a comment, sign in

Explore topics